RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: The Company designs, develops, manufactures, and markets safety syringes (primarily the VanishPoint® syringe) and blood collection tube holders. Operations are based in Little Elm, Texas, with significant manufacturing capacity outsourced to Double Dove in China (approximately 73% of units in the first nine months of 2006). The Company faces market access challenges due to the dominance of Becton Dickinson & Co. (BD) and relies on litigation settlements and international contracts (e.g., PATH) for revenue growth.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total sales increased 16.2% year-over-year (from $16.3M to $18.9M) for the nine months ended September 30, driven by a 151.3% increase in international sales (primarily PATH shipments) and a 7.5% increase in domestic sales. However, net sales (excluding reimbursed discounts) decreased slightly.
• Profitability: The Company reported a net loss of $2.03M for the nine months ended September 30, 2006, compared to a net loss of $1.56M in the prior year period. Loss from operations widened significantly to $4.14M from $2.99M.
• Cost Structure: Operating expenses increased 19.7% to $10.11M, driven by higher sales and marketing costs (additional personnel, trade shows) and R&D costs (catheter development). Cost of sales increased due to higher volumes and royalty expenses.
• Cash Flow: Net cash used by operating activities improved significantly to $(192,550) compared to $(3.96M) in the prior year, largely due to a decrease in accounts receivable and an increase in accounts payable.
• Inventory: Inventories increased 51.5% to $5.0M, primarily due to higher raw materials and finished goods to support increased production.

Guidance, Outlook, and Risks

• Discount Program Impact: The Company has reached the $8.0 million cumulative reimbursement cap for its discount program under a litigation settlement. Discounts offered to participating facilities through December 31, 2006, in excess of this cap will negatively impact gross profit in the fourth quarter of 2006.
• Market Access: Management continues to face barriers to hospital market access due to monopolistic practices by BD. If cash from operations and settlements becomes insufficient, the Company may implement cost-cutting measures, including workforce reductions and deferral of royalty payments.
• International Growth: The Company anticipates continued growth in international sales, particularly through the PATH program in Africa. A licensing agreement with Baiyin Tonsun Medical Device Co., Ltd. (BTMD) in China is expected to generate royalties by the end of 2006 or Q1 2007.
• Liquidity: The Company maintains a strong liquidity position with cash comprising 69.4% of total assets. Management believes current capitalization is sufficient to fund operations and manufacturing upgrades.
• Risks: Key risks include reliance on a single Chinese manufacturer (Double Dove) for 73% of production, uncertainty regarding the deductibility of certain interest and option expenses for tax purposes, and the potential for further declines in gross margins due to the discount program.

Investor Verification Checklist

• Discount Program Cap: Verify the exact financial impact of the $8.0 million reimbursement cap on Q4 2006 gross margins.
• Preferred Stock Arrears: Review the significant accumulated dividends in arrears on Series I through V Class B Convertible Preferred Stock (totaling over $11.8 million in arrearage).
• Supply Chain Concentration: Assess the risk associated with 73% of production being outsourced to Double Dove in China.
• Tax Position: Monitor the outcome of the Company's evaluation of tax positions regarding interest and option expense deductibility under FIN 48.
• BTMD Royalties: Track the timeline for the first royalty payment from the Chinese licensing partner, currently expected by Q1 2007.